Shenzhen-based company Chipscreen Biosciences Co., Ltd. has shared that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has recently obtained Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone was announced on July 31, 2025. The approval signifies a significant step forward for the company in advancing its pharmaceutical research and development efforts in the United States.